

Prescription drug prices public hearing agenda

Date/time:

Thursday, Dec. 4, 2025, 1:30 to 4 p.m.

Location:

Online: Zoom webinar <http://dcbspage.org/RXDRUGPRICEHEARING2025>

Phone: 669-254-5252 (toll-free); ID: 160 083 9415.

Oregonians are encouraged to submit testimony and questions about drug pricing and suggest future hearing topics. Once the meeting starts, the public can sign up to give testimony using the Zoom chat window or email rx.prices@dcbs.oregon.gov before the date of the hearing.

Facilitator

- TK Keen (he/him), acting Oregon insurance commissioner

Moderators

- Sen. Deb Patterson (she/her)
- Sen. Diane Linthicum
- Rep. Emerson Levy (she/her)
- Rep. Rob Nosse (he/him)

Agenda**Welcome and introductions – 1:30 to 1:40 p.m.**

- TK Keen
- Sarah Young (she/her), Prescription Drug Affordability Board executive director, DFR

Program staff presentation – 1:40 to 2:10 p.m.

- Sofia Parra (she/her), program coordinator, Drug Price Transparency Program, DFR
 - Program information.
- Taran Heins (he/him), research analyst, DFR
 - Reporting highlights from the drug price transparency annual report from manufacturers, pharmacy benefit managers (PBMs), and insurers.
- Numi Rehfield-Griffith (she/her), senior policy advisor, DFR
 - Legislative policy recommendations.

First public comment period – 2:10 to 2:20 p.m.

Sign up during the meeting in the Zoom chat or email rx.prices@dcbs.oregon.gov before the hearing.

First invited panel – 2:20 to 3:05 p.m.

Topic: Biologics and biosimilars – interchangeability and adoption

- Benjamin N. Rome (he/him), M.D., MPH, assistant professor of medicine, Harvard Medical School and Brigham and Women's Hospital
- Alex Keeton (he/him), executive director, Biosimilars Council, Association for Accessible Medicines
- Michael Reilly, Esq. (he/him), executive director, Alliance for Safe Biologic Medicines

Second invited panel – 3:05 to 3:50 p.m.

Topic: Innovative prescription financing solutions

- Daniel Ollendorf (he/him), Ph.D., MPH, chief scientific officer and director of health technology assessment methods and engagement, Institute for Clinical and Economic Review
- Deborah “Dee” Weston (she/her), J.D., pharmacy program policy advisor, Oregon Health Authority
- Sharon Lamberton (she/her), M.S., R.N., deputy vice president state policy and external outreach, PhRMA

Second public comment period – 3:50 p.m. until end of hearing

Sign up during the meeting in the Zoom chat or email rx.prices@dcbs.oregon.gov before the hearing.

Notes

Members of the public who want to provide testimony can sign up in the Zoom chat during the public hearing or email rx.prices@dcbs.oregon.gov before the hearing. Questions and written testimony can be sent to rx.prices@dcbs.oregon.gov before or after the hearing.

Public hearing webpage: <https://dfr.oregon.gov/drugtransparency/Pages/public-hearings.aspx>. The presentations and testimony will be posted on our webpage soon after the hearing, and the recording will be available by Dec. 20.